PDS Biotechnology (NASDAQ:PDSB) announced its quarterly earnings data on Thursday. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.28), Yahoo Finance reports.
PDS Biotechnology stock opened at $2.92 on Friday. The company has a quick ratio of 5.35, a current ratio of 5.35 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $15.53 million, a price-to-earnings ratio of -0.16 and a beta of 2.38. PDS Biotechnology has a 12 month low of $2.80 and a 12 month high of $17.00.
Several research firms have commented on PDSB. HC Wainwright began coverage on PDS Biotechnology in a research report on Tuesday. They issued a “buy” rating and a $7.00 target price for the company. Chardan Capital began coverage on PDS Biotechnology in a research report on Wednesday, October 23rd. They issued a “buy” rating and a $10.00 target price for the company.
PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. The company develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers.
Further Reading: Rule of 72
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.